C.R. Bard Inc. (BCR)
BCR (NYSE:Health Services)
$110.58
-1.22
-1.09%
Today's Range: 110.41 - 112.36 |
BCR Avg Daily Volume: 659,600
| Last Update: 06/19/13 - 4:02 PM EDT |
| Volume: 515,977 |
| YTD Performance: 13.14%
|
| Open: $111.77 |
| Previous Close: $111.80 |
| 52 Week Range: $93.69 -
$112.36 |
| Oustanding Shares: 80,481,858 |
| Market Cap: 8,997,871,724 |
6-Month Chart
TheStreet Ratings Grade for BCR
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
4 |
4 |
4 |
4 |
| Moderate Buy |
1 |
1 |
1 |
2 |
| Hold |
10 |
9 |
10 |
10 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
2 |
2 |
2 |
2 |
| Mean Rec. |
2.66 |
2.64 |
2.66 |
2.63 |
| Latest Dividend: |
0.21 |
| Latest Dividend Yield: |
0.75% |
| Dividend Ex-Date: |
07/18/13 |
| Price Earnings Ratio: |
19.82 |
|
| Price Earnings Comparisons: |
| BCR |
Sector Avg. |
S&P 500 |
| 19.82 |
19.80 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
9.51%
|
5.75%
|
37.71%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
2.10 |
0.17 |
0.05 |
| Net Income |
61.60 |
0.15 |
0.05 |
| EPS |
66.90 |
0.34 |
0.10 |
| Earnings for BCR: |
| EBITDA |
0.95B |
| Revenue |
2.96B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.38 |
$1.66 |
$6.25 |
$7.67 |
| Number of Analysts |
13 |
12 |
15 |
13 |
| High Estimate |
$1.41 |
$1.75 |
$6.32 |
$7.84 |
| Low Estimate |
$1.37 |
$1.41 |
$6.00 |
$7.47 |
| Prior Year |
$1.62 |
$1.64 |
$6.57 |
$6.25 |
| Growth Rate (Year over Year) |
-14.62% |
0.97% |
-4.87% |
22.73% |
| Apr 04, 2013 | 1:41 PM EDT
Occasionally there is unusual technical synchronization on multiple timeframes.
Feb 22, 2013 | 8:21 AM EST
BCR was downgraded to Sell from Neutral, Goldman Sachs said. $95 price target. Market giving too much credit for outer eyar revenue/EPS...
Feb 05, 2013 | 11:32 AM EST
Jan 14, 2013 | 8:09 AM EST
BCR was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $114 price target. Company offers low-risk, double-digit digi...
Jan 03, 2013 | 8:24 AM EST
BCR was downgraded from Equal-weight to Underweight, Morgan Stanley said. $91 price target. Company has a premium valuation, but is gro...
Jan 02, 2013 | 8:07 AM EST
BCR was upgraded to Overweight from Neutral, JP Morgan said. Anticipate favorable resolution of Gore patent litigation.
Dec 19, 2012 | 11:41 AM EST
Portfolio Mgr. David Peltier uncovers a low-dollar healthcare stock with big growth potential.
Dec 19, 2012 | 7:41 AM EST
BCR was initiated with an Outperform rating, JMP Securities said. $118 price target. Upcoming Gore settlement should be a near-term cat...
Dec 05, 2012 | 5:30 AM EST
Portfolio Mgr. David Peltier analyzes a low-dollar stock on the verge of a potential turnaround.
Jul 26, 2012 | 7:57 AM EDT
Shares of BCR downgraded to Hold from Buy, Jefferies said. $94 price target. Macro headwinds and valuation.
